Close Menu

This article has been updated from a previous version to include comments made by NeoGenomics executives during the company's earnings call.

NEW YORK – NeoGenomics on Thursday reported a 40 percent year-over-year jump in its Q4 revenues.

The cancer genetic testing company reported revenues of $106.9 million for the three-month period ended Dec. 31, 2019, up from revenues of $76.5 million in the same period last year and beating the consensus Wall Street estimate of $104.2 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.